Key Highlights

  • Bridgeline Digital (NASDAQ:BLIN): up 20.77 percent to USD 0.7971, with cash of about USD 1.0 million at fiscal year end.
  • CalciMedica (NASDAQ:CALC): up 15.07 percent to USD 1.68, with USD 18.6 million of cash at June 30, 2026.
  • Gyre Therapeutics (NASDAQ:GYRE): up 11.96 percent to USD 5.10, with second quarter Revenue of USD 29.1 million.
  • Swvl (NASDAQ:SWVL): up 10.08 percent to USD 4.15, with first half revenue of USD 16.2 million.
  • JE Cleantech (NASDAQ:JCSE): up 9.82 percent to USD 1.79, with first half revenue up 221 percent.

Bridgeline Digital (NASDAQ:BLIN): A Sub-Dollar Jump With a Small Cash Balance

Bridgeline Digital (NASDAQ:BLIN) gained 20.77 percent to USD 0.7971 in pre-market trading on November 2, 2026. No press release or filing dated that day was identified, so the catalyst is not confirmed. Low price and limited float may play a part, though that is an interpretation and not a company statement.

A release dated October 6, 2026 reported fiscal 2026 annual Recurring Revenue sales of USD 2.2 million from 75 sales for its HawkSearch platform. Cash was approximately USD 1.0 million, and a USD 3.95 million at-the-market offering was set up on July 14, 2026. As a penny stock, it carries dilution and Nasdaq bid price risk.

CalciMedica (NASDAQ:CALC): Biotech Gains Without a Filing

CalciMedica (NASDAQ:CALC) was up 15.07 percent to USD 1.68 in pre-market trading on November 2, 2026. No announcement dated between late October and that day was identified, so the move looks more like momentum in a thinly traded, low-priced share. That is a measured reading, not a confirmed cause.

The clinical-stage company develops Auxora and now focuses on pulmonary hypertension, with Phase 1b data expected in mid-2027. Cash was USD 18.6 million at June 30, 2026. A one-for-five reverse split took effect on August 31, 2026, and warrants from a June 2026 private Placement could dilute holders.

Gyre Therapeutics (NASDAQ:GYRE): A Possible Rebound After a Gap Down

Gyre Therapeutics (NASDAQ:GYRE) was up 11.96 percent to USD 5.10 in pre-market trading on November 2, 2026. No company press release, filing or trial readout dated between late October and that day was found. A market data page from November 1, 2026 described the shares as Gapping down, so part of the gain may be a rebound. That is a market observation, not a company statement.

Second quarter revenue was USD 29.1 million, down 2 percent, and the net loss widened to USD 14.3 million from USD 2.2 million. Cash, deposits and investments were USD 103.2 million at June 30, 2026. The Astellas collaboration ended in March 2026.

Swvl (NASDAQ:SWVL): Momentum on Thin Extended-Hours Volume

Swvl (NASDAQ:SWVL) was up 10.08 percent to USD 4.15 in pre-market trading on November 2, 2026. No announcement dated late October or that day was identified. The latest release found, dated October 8, 2026, reported first half revenue up 59 percent to USD 16.2 million.

Gross Margin slipped to 18.2 percent from 21.5 percent, and the operating loss widened to USD 0.57 million. Cash was USD 2.1 million at June 30, 2026, before a strategic Investment of USD 13 million announced on August 25, 2026. With shares under USD 5, this Penny Stock faces volatility, thin Liquidity and further share issuance risk.

JE Cleantech (NASDAQ:JCSE): A Profit Turnaround in the Background

JE Cleantech (NASDAQ:JCSE) was up 9.82 percent to USD 1.79 in pre-market trading on November 2, 2026. No press release or filing dated that day was identified. The move may reflect interest in the first half results released on October 20, 2026, along with a small float that can magnify extended-hours swings.

First half revenue rose 221 percent to SGD 20.8 million, and Net Income was SGD 1.7 million against a net loss of SGD 0.8 million a year earlier. The release gave no cash figure in the material reviewed, so liquidity cannot be assessed. Large orders came from a single existing customer, and this penny stock may dilute holders if it raises capital.

Where Things Stand

All five names rose between 9.82 percent and 20.77 percent with no announcement from November 2, 2026 identified, so the gains are best read as price action and not confirmed news. Four trade below USD 5 and share familiar penny stock risks, namely thin liquidity, dilution and listing pressure. Gyre, at USD 5.10, has a larger cash balance but a widening net loss.

Markers to watch include Bridgeline's use of its at-the-market program, CalciMedica's third quarter results due in November, Swvl's deployment of its August proceeds, Gyre's third quarter results and JE Cleantech's delivery progress. Pre-market gains on light Volume can fade once regular trading opens.